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Abstract
Treatment options for patients with lower risk non-del(5q) myelodysplastic syndromes (MDS) who fail erythroid 
stimulating agents are restricted to one of the hypomethylating drugs with an expected response rate of ~50%. 
Ezatiostat HCl, an agent with the potential for producing multi-lineage responses in this population is currently in 
clinical investigation phase. This case report describes a 77 year old male who received less than two cycles of therapy 
with ezatiostat HCl which had to be aborted due to intolerable side effects, but which produced a sustained 
normalization of all three blood counts. This trilineage response has now lasted for more than a year. Interestingly, the 
patient began with a del(5q) abnormality and responded briefly to lenalidomide. Upon relapse of the anemia, a bone 
marrow showed the disappearance of the del(5q) but the appearance of a new clonal abnormality t(2;3). Given that the 
patient had a complete cytogenetic response to a truncated exposure to lenalidomide followed by a trilineage 
response to an even briefer course of ezatiostat HCl suggests a potential role for ezatiostat HCl in del(5q) patients who 
relapse following lenalidomide.
Background
Myelodysplastic syndromes (MDS) are a group of bone
marrow stem cell disorders which generally affect the
elderly (median age of 70 years) and present with the par-
adox of a variable cytopenia with a cellular marrow. Prog-
nostically, these syndromes are broadly divided into those
having a lower or higher risk of transformation to acute
myeloid leukemia (AML) on the basis of three variables;
the number of cytopenias, percentage of bone marrow
blasts and cytogenetics [1]. Consequently, the course of
MDS and response to therapy vary between the prognos-
tic categories. Allogeneic stem cell transplant offers the
only potential for cure to these patients; unfortunately,
because of the advanced age, this is an option for only a
select few. The primary goal of palliative therapy in lower
risk patients is to improve the cytopenias while that for
the higher risk MDS, in addition, is to arrest the expand-
ing population of blasts [2]. Currently, there are three
FDA approved drugs; lenalidomide is indicated for the
treatment of transfusion dependent MDS patients with
del(5q) and lower risk disease while the two hypomethy-
lating agents (azacytidine and decitabine) are approved
for all categories. With the exception of del(5q) patients,
the response rate is approximately 50%, highlighting the
need for clinical trials of new agents.
Ezatiostat (HCl) is a glutathione analog which has dem-
onstrated in vivo hematopoietic stimulatory activity in
several clinical trials is one such novel agent currently
undergoing clinical investigation [3-7]. Here, we report
the case of a patient with a lower risk MDS who
responded unexpectedly well to an abbreviated course of
this investigational agent.
Case Presentation
A 77-year-old Caucasian male with a history of reflux
esophagitis requiring fundoplication was found to be
pan-cytopenic in December 2007 (WBC 3.0 × 103/μL,
hemoglobin 9.5 g/dL, and platelet count 115,000/μL). A
bone marrow (BM) biopsy on 3/17/08 was consistent
with a diagnosis of MDS with a mildly hypocellular mar-
row, minimal dyserythropoiesis, less than 5% blasts and
cytogenetics showing 17 of 20 metaphases with a
del(5q)(q13q33). He was subsequently started on lenali-
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increasing to 11-12 gram range and platelet counts
increasing to 130,000 - 150,000 range. The counts
decreased within 6 months of an initial response and a
repeat BM in 08/27/08 revealed a normocellular marrow
with dysplastic changes in the myeloid and erythroid
series and mildly increased blasts at 6%. Interestingly, the
del(5q) abnormality had disappeared, however, a new t(2;
3) translocation in 16 of 20 metaphases was seen. The
patient discontinued lenalidomide, and offered therapy
with hypomethylating agents which he refused. The
patient was subsequently referred to us in September
2008. He had an erythropoietin level of 1840, serum iron
44, ferritin 112, TIBC 222, folic acid > 24, and vitamin
B12 level of 672. His peripheral blood was negative for
the JAK2 V617F point mutation, and showed normal
expression of CD55 and CD59. The patient agreed to par-
ticipate in a randomized, open label, multi-center phase 2
study comparing two dose schedules of Ezatiostat HCl for
Low to Intermediate -1 risk MDS and was randomized to
receive ezatiostat at 1500 mg p.o. b.i.d. for 14 days of a 21-
day cycle for a maximum of 24 weeks. The patient started
his first cycle on 10/23/08, with his second cycle begin-
ning on 11/13/08. However, five days into his second
treatment cycle he was withdrawn from the study (11/18/
08) due to a grade 3 acute gastritis and biopsy proven
candida esophagitis. He was started on proton pump
inhibitors and oral antifungal therapy to which he
responded well. The gastritis resolved completely with
medical management within two weeks.
Figure 1 shows the striking improvement in all three
blood counts beginning with ezatiostat HCl treatment
initiation and continuing to remain high a year post ther-
apy. These results are impressive when one considers that
the patient received treatment for less than one and half
cycles. Pre-study CBC showed a baseline WBC of 1.5 to
2.5 × 103/μL, hemoglobin of 9 to10 g/dL, and platelet
count of 50,000 to 100,000/μL. Post study, patient's CBC
has remained steady with a WBC of approximately 4 to
4.5 × 103/μL, hemoglobin above 13 grams/dL, and a
Figure 1 Graph A: Hemoglobin curve. Graph B: White blood cell curve. Graph C: Platelet curve.
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required any further therapy for his underlying MDS
including any use of growth factors. The patient declined
a repeat bone marrow exam.
Ezatiostat HCl, a glutathione analog prodrug, has
shown significant stimulatory and prodifferentiating
activity in vitro in human bone marrow progenitor cul-
tures, as well as in several in vivo preclinical models of
myelopoiesis [3-5]. Initially ezatiostat hydrochloride lipo-
somes for injection (IV formulation) were evaluated in
MDS in a Phase 1-2a study with observed good tolerabil-
ity and HI responses [6]. An oral formulation of ezatiostat
HCl tablets in a phase 1 study was recently published [7].
In this study no dose-limiting toxicities were observed.
The most common grade 1 or 2, respectively, treatment-
related adverse events were non-hematologic: nausea
(56%, 9%), diarrhea (36%, 7%), vomiting (24%, 7%),
abdominal pain (9%, 0%), constipation (4%, 9%), anorexia
(3%, 7%), and dyspepsia (3%, 7%). Forty five patients were
treated on the Phase I dose escalation study and seven-
teen hematologic improvement (HI) responses were
observed. While HI was seen at even the lowest dose, 11/
17 HI responses were at doses between 4000 to 6000 mg/
day. HI responses included 3 bilineage and 1 complete
cytogenetic response with improved transfusion require-
ments and in some cases transfusion independence. Cur-
rently a phase 2 study to determine the optimal dosing
schedule for oral ezatiostat HCl is underway, and our
patient was on one arm of this study.
We report this unique case, as the patient received
therapy with oral ezatiostat HCl tablets for less than 2
cycles, but has shown an impressive hematologic
response that has lasted for over a year. Interestingly, this
patient presented with a del(5q) abnormality which dis-
appeared after a short course of lenalidomide, only to be
replaced by a new clonal abnormality t(2;3) upon relapse.
Despite resistance to lenalidomide and the appearance of
this new clone, the patient experienced a durable trilin-
eage response to a very short and aborted course of eza-
tiostat HCl suggesting either an exceptionally responsive
disease or a potential role for ezatiostat HCl in the treat-
ment of patients who relapse following lenalidomide
therapy.
Conclusion
In conclusion, this case highlights two important obser-
vations; first that even a brief exposure to ezatiostat HCl
produced a striking and sustained hematologic response,
and secondly that this occurred in a patient who relapsed
after lenalidomide therapy. As MDS is a heterogeneous
disease, it would be important to identify the subset of
MDS patients, who like our patient above, may receive
clinical benefit from this agent.
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